BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 12635139)

  • 1. Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium.
    Gulyás M; Hjerpe A
    J Pathol; 2003 Apr; 199(4):479-87. PubMed ID: 12635139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of genes coding for proteoglycans and Wilms' tumour susceptibility gene 1 (WT1) by variously differentiated benign human mesothelial cells.
    Gulyás M; Dobra K; Hjerpe A
    Differentiation; 1999 Oct; 65(2):89-96. PubMed ID: 10550542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of mesothelioma cells is influenced by the expression of proteoglycans.
    Dobra K; Andäng M; Syrokou A; Karamanos NK; Hjerpe A
    Exp Cell Res; 2000 Jul; 258(1):12-22. PubMed ID: 10912783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome.
    Kumar-Singh S; Jacobs W; Dhaene K; Weyn B; Bogers J; Weyler J; Van Marck E
    J Pathol; 1998 Nov; 186(3):300-5. PubMed ID: 10211120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth factors regulate the expression profile of their syndecan co-receptors and the differentiation of mesothelioma cells.
    Dobra K; Nurminen M; Hjerpe A
    Anticancer Res; 2003; 23(3B):2435-44. PubMed ID: 12894525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas.
    Saqi A; Yun SS; Yu GH; Alexis D; Taub RN; Powell CA; Borczuk AC
    Diagn Cytopathol; 2005 Aug; 33(2):65-70. PubMed ID: 16007640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and expression of mRNA encoding for different versican splice variants is related to the aggregation of human epithelial mesothelioma cells.
    Syrokou A; Dobra K; Tzanakakis GN; Hjerpe A; Karamanos NK
    Anticancer Res; 2002; 22(6C):4157-62. PubMed ID: 12553048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.
    Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K
    Pathol Int; 2007 Apr; 57(4):190-9. PubMed ID: 17316414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis.
    Barbareschi M; Maisonneuve P; Aldovini D; Cangi MG; Pecciarini L; Angelo Mauri F; Veronese S; Caffo O; Lucenti A; Palma PD; Galligioni E; Doglioni C
    Cancer; 2003 Aug; 98(3):474-83. PubMed ID: 12879463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Podoplanin is a useful marker for identifying mesothelioma in malignant effusions.
    Hanna A; Pang Y; Bedrossian CW; Dejmek A; Michael CW
    Diagn Cytopathol; 2010 Apr; 38(4):264-9. PubMed ID: 20146302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of proteoglycan core proteins in human bone marrow stroma.
    Schofield KP; Gallagher JT; David G
    Biochem J; 1999 Nov; 343 Pt 3(Pt 3):663-8. PubMed ID: 10527946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
    Afify AM; Stern R; Michael CW
    Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the proteoglycans versican and mel-CSPG in dysplastic nevi.
    Touab M; Arumi-Uría M; Barranco C; Bassols A
    Am J Clin Pathol; 2003 Apr; 119(4):587-93. PubMed ID: 12710131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
    Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
    Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of syndecan-1 (CD138) in nasopharyngeal carcinoma is correlated with advanced stage and poor prognosis.
    Chen CL; Ou DL
    Hum Pathol; 2006 Oct; 37(10):1279-85. PubMed ID: 16949936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Large matrix proteoglycans, versican and perlecan, are expressed and secreted by human leukemic monocytes.
    Makatsori E; Lamari FN; Theocharis AD; Anagnostides S; Hjerpe A; Tsegenidis T; Karamanos NK
    Anticancer Res; 2003; 23(4):3303-9. PubMed ID: 12926067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Localization of syndecan-1 in human gastric mucosa associated with ulceration.
    Tanabe H; Yokota K; Kohgo Y
    J Pathol; 1999 Feb; 187(3):338-44. PubMed ID: 10398089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis.
    Kumar-Singh S; Segers K; Rodeck U; Backhovens H; Bogers J; Weyler J; Van Broeckhoven C; Van Marck E
    J Pathol; 1997 Jan; 181(1):67-74. PubMed ID: 9072005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: A logistic regression analysis.
    Cakir E; Demirag F; Aydin M; Unsal E
    Diagn Cytopathol; 2009 Jan; 37(1):4-10. PubMed ID: 18973123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.